Key result
Baseline data of 2,970 Chinese Han patients undergoing coronary angiography showed 67.3% had hypertension and 35.2% had diabetes, establishing a cohort to evaluate new biosignatures for CAD risk.
Why the study?
Atherosclerotic CAD risk assessment using conventional risk factors shows moderate performance with residual risk, prompting identification of new biosignatures including metabolomics, lifestyle biomarkers, and biological age.
Do new biosignatures (metabolomics, lifestyle biomarkers, biological age) predict CAD and subsequent cardiovascular events in patients undergoing coronary angiography?
Cohort (n=2,970)
No
Do new biosignatures (metabolomics, lifestyle biomarkers, biological age) predict CAD and subsequent cardiovascular events in patients undergoing coronary angiography?
The Beijing Hospital Atherosclerosis Study is a prospective cohort of 2,970 patients undergoing coronary angiography designed to identify and validate new biosignatures for predicting CAD and cardiovascular events.
Provides baseline for prospective Chinese angiography cohort; leaves open whether new biosignatures improve CAD prediction.
Background: The atherosclerotic coronary artery disease (CAD) risk assessment based on conventional risk factors have only moderate performance, and residual risks still exist. Thus, we reported here a cohort study that aims to identify and validate the new biosignatures (especially the metabolomics, lifestyle biomarkers and biological age), and elucidate their predictive effect on CAD and subsequent cardiovascular events. Methods: This prospective, single-center, cohort study commenced in March 2017 and seeks to examine patients undergoing coronary angiography (CAG) at the Beijing Hospital. Patients' baseline demographic and medical history data are captured by questionnaires. Blood samples are taken before CAG for clinical laboratory tests and metabolomics analyses. Traditional CAD risk factors are analyzed by routine assays. CAD-related metabolites from different metabolic pathways and lifestyle biomarkers are measured by liquid chromatography-tandem mass spectrometry methods. Biological ages are calculated based on the laboratory and metabolomics data. The enrolled patients attend annual follow-up examinations for 10 years. The primary end points are the composite end points of major adverse cardiovascular events, including death from any cause, non-fatal myocardial infarction, and non-fatal stroke. Quality management and control are carried out through the entire research process, including standardized baseline and follow-up investigation, intra- and inter-run quality controls for laboratory measurements, etc. Results: Baseline data of the enrolled 2,970 patients from 2017 to 2020 were collected and are presented in this article. Among them, there were more males (62.5%) than females, and the patients tended to be old and overweight. The percentages of diagnosed hypertension and diabetes were 67.3% and 35.2%, respectively. A total of 8.5% had a family history of premature CAD. Their lipid profiles were within the normal range, probably due to the use of statins. Conclusions: This study has successfully initiated an investigation into the roles of new biosignatures in predicting CAD among Chinese Han patients undergoing CAG. To the best of our knowledge, this cohort is the first study systematically focusing on the association of lifestyle biomarkers and biological age with CAD risk. Findings from this study will provide biomarkers to discriminate the presence of CAD and to predict subsequent cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a cohort in Coronary artery disease (n=2,970). New biosignatures (metabolomics, lifestyle biomarkers, biological age) was evaluated on Composite of major adverse cardiovascular events, including death from any cause, non-fatal myocardial infarction, and non-fatal stroke. Baseline data of 2,970 Chinese Han patients undergoing coronary angiography showed 67.3% had hypertension and 35.2% had diabetes, establishing a cohort to evaluate new biosignatures for CAD risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: